Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...

Boston, MA, USA and Oxford, UK -- 12 February 2026, Vitaccess, a leader in generating science-driven real-world evidence, has entered into an exclusive partnership with the Myasthenia Gravis ...

A nomogram was developed to identify high-risk myasthenia gravis patients, focusing on those with bulbar weakness. Key risk factors include MGFA stage 3/4, thymoma presence, inability to lie flat, and ...

A total of 18 abstracts will be presented at AANEM and the MGFA scientific session, highlighting UCB's dedication to driving advancements in gMG treatment. These presentations will cover data on ...

The positions in the table below reflect the Myasthenia Gravis Foundation of America (MGFA)'s position overall, domestically, within their sector, and in various subject areas based on their Share.

Decisions about thymectomy in myasthenia gravis (MG) depend on several variables. Two important categories are whether the patient's thymus gland has thymoma or not and what type of autoantibodies, if ...

SAN FRANCISCO — Interim results from an ongoing phase 2/3 trial suggested that intravenous efgartigimod (Vyvgart) significantly reduced disease activity in adolescents with acetylcholine receptor ...

—A retrospective analysis of patients with acetylcholine receptor antibody (AChR-Ab)-positive generalized myasthenia gravis (MG) who underwent thymectomy found that a majority of them had good ...

No articles found. Myasthenia Gravis Foundation of America (MGFA) did not contribute to any primary research papers from Nature Index journals in the current 12 month window. Identify research ...

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients Oct. 29, 2025 11:00 AM ET argenx SE (ARGNF) ...